[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018001918A - Aplicación cuantitativa periorbital de farmacos oftalmologicos. - Google Patents

Aplicación cuantitativa periorbital de farmacos oftalmologicos.

Info

Publication number
MX2018001918A
MX2018001918A MX2018001918A MX2018001918A MX2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A MX 2018001918 A MX2018001918 A MX 2018001918A
Authority
MX
Mexico
Prior art keywords
ophthalmology
peri
drugs
quantitative
orbital
Prior art date
Application number
MX2018001918A
Other languages
English (en)
Inventor
Woodward David
Wang Weizhen
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of MX2018001918A publication Critical patent/MX2018001918A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se dirige a métodos para disminuir la presión intraocular en un paciente que padece presión intraocular elevada o glaucoma y para tratar la enfermedad ocular administrando un fármaco a la piel periorbital del paciente.
MX2018001918A 2015-08-19 2016-08-17 Aplicación cuantitativa periorbital de farmacos oftalmologicos. MX2018001918A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/829,789 US9820954B2 (en) 2015-08-19 2015-08-19 Quantitative peri-orbital application of ophthalmology drugs
PCT/US2016/047230 WO2017031137A1 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Publications (1)

Publication Number Publication Date
MX2018001918A true MX2018001918A (es) 2018-11-09

Family

ID=58051248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001918A MX2018001918A (es) 2015-08-19 2016-08-17 Aplicación cuantitativa periorbital de farmacos oftalmologicos.

Country Status (9)

Country Link
US (1) US9820954B2 (es)
EP (1) EP3337474A4 (es)
JP (1) JP6924429B2 (es)
KR (1) KR102685479B1 (es)
CN (1) CN108135873A (es)
AU (1) AU2016308105B2 (es)
CA (1) CA2992483C (es)
MX (1) MX2018001918A (es)
WO (1) WO2017031137A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
GB2580226B (en) * 2017-06-30 2022-08-31 Jenivision Inc Formulations for hair growth
EP4288043A1 (en) * 2021-02-05 2023-12-13 Jenivision Inc. Compositions and methods for periorbital administration of ep2 receptor agonists
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3990444A (en) 1972-11-22 1976-11-09 Vial S.A.R.L. Blood transfusion apparatus
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
CA2563365A1 (en) 2004-04-23 2005-11-03 Mystic Pharmaceuticals, Inc. Multiple unit dose drug delivery system
US7226435B2 (en) 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
NZ563984A (en) * 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
WO2007127333A2 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
EP2056809A1 (en) 2006-08-28 2009-05-13 Senju Pharmaceutical Co., Ltd. Ophthalmic percutaneous absorption type preparation
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
US9173991B2 (en) 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
JP2011503061A (ja) 2007-11-08 2011-01-27 アーシエックス セラピューティックス， インコーポレイテッド 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物
KR20100131976A (ko) * 2008-02-05 2010-12-16 아스터랜드 유케이 리미티드 고 안압증의 치료를 위한 디플루오로바이페닐아미드 유도체
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2493474B1 (en) 2009-10-30 2019-09-04 Intratus, Inc. Methods and compositions for sustained delivery of drugs
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
EP2544757A4 (en) 2010-03-09 2013-11-06 Toxcure Inc MICRONADEL DEVICE FOR NASAL DISTRIBUTION
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
GB2482691B (en) 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
EA026702B1 (ru) * 2011-09-16 2017-05-31 Санофи Производные анилина, их получение и терапевтическое применение
CN108175742B (zh) 2011-11-15 2021-10-22 阿勒根公司 环孢菌素形式2的持续作用型制剂
WO2014045300A2 (en) 2012-09-03 2014-03-27 Fdc Limited "topical drug delivery system"
CN203379477U (zh) 2012-12-14 2014-01-08 上海市第七人民医院 一种微针滚轮装置

Also Published As

Publication number Publication date
WO2017031137A1 (en) 2017-02-23
EP3337474A1 (en) 2018-06-27
JP6924429B2 (ja) 2021-08-25
KR20180042348A (ko) 2018-04-25
CA2992483A1 (en) 2017-02-23
AU2016308105A1 (en) 2018-02-15
US9820954B2 (en) 2017-11-21
US20170049734A1 (en) 2017-02-23
AU2016308105B2 (en) 2021-05-27
KR102685479B1 (ko) 2024-07-15
CA2992483C (en) 2024-03-19
EP3337474A4 (en) 2019-04-10
JP2018528169A (ja) 2018-09-27
CN108135873A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
UY33481A (es) Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201790889A1 (ru) Офтальмологический раствор
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
EP3405159A4 (en) TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION
MY199237A (en) Methods of treating ocular conditions
SG11201408323RA (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
AR092842A1 (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
EP4245295A3 (en) Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
TN2016000259A1 (en) Salbutamol (albuterol) eye protective medicament.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
BR112012023749A2 (pt) método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
Yu et al. Using spectral-domain optical coherence tomography imaging to identify the presence of retinal silicone oil emulsification after silicone oil tamponade.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
Pasyechnikova et al. Report on International Scientific Conference" Filatov Memorial Lecture-2016" dedicated to 140th Birth Anniversary of Academician VP Filatov
WO2019013518A3 (ko) 단풍나무 잎 추출물을 포함하는 안압 저하용 조성물
PL398967A1 (pl) Zastosowanie kwasu loganowego w terapii jaskry
PH12017501796A1 (en) Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient